Zobrazeno 51 - 60
of 320
pro vyhledávání: ''
Autor:
Klaus Brasso, Peter Iversen, John Thomas Helgstrand, Birgitte Grønkær Toft, Ben Vainer, Nina Klemann, Martin Andreas Røder
Publikováno v:
European journal of cancer (Oxford, England : 1990). 84
The diagnostic characteristics of men who eventually die from prostate cancer (PCa) and the extent to which early diagnostic strategies have affected these characteristics are unclear. We aimed to investigate trends in survival and clinical presentat
Autor:
Moritz Jesinghaus, Alexander Muckenhuber, Helmut Friess, Günter Kloeppel, Wilko Weichert, Björn Konukiewitz, Güralp O. Ceyhan, Carsten Denkert, Carsten Jäger, Ihsan Ekin Demir, Anna Melissa Schlitter, Marcus Bahra
Publikováno v:
European journal of cancer (Oxford, England : 1990). 84
The UICC TNM (tumour-node-metastasis) staging system for pancreatic ductal adenocarcinoma (PDAC) has been a matter of debate over decades because survival prediction based on T stages was weak and unreliable. To improve staging, the recently publishe
Publikováno v:
European journal of cancer (Oxford, England : 1990). 84
Introduction Underutilisation of radiotherapy has been observed worldwide. To evaluate the current situation in Belgium, optimal utilisation proportions (OUPs) adopted from the European SocieTy for Radiotherapy and Oncology – Health Economics in Ra
Publikováno v:
European journal of cancer (Oxford, England : 1990). 81
Autor:
Jan Frisell, Lars Holmberg, Jonas Bergh, Fredrik Pontén, Irma Fredriksson, Hanna Fredholm, Nicholas P. Tobin, Linda S. Lindström, Kristina Magnusson, Henrik Lindman
Publikováno v:
European journal of cancer (Oxford, England : 1990). 84
Compared to middle-aged women, young women with breast cancer have a higher risk of systemic disease. We studied expression of proliferation markers in relation to age and subtype and their association with long-term prognosis.Distant disease-free su
Autor:
A. Jagenburg, Thomas Kirchner, Lisa Miller-Phillips, S.-E. Al-Batran, Swantje Held, Christoph Kahl, Martina Stauch, Sebastian Stintzing, M. Moehler, Werner Scheithauer, G. Seipelt, Dominik Paul Modest, Thomas Decker, Tobias Heintges, Andreas Jung, Alexander Kiani, L. Fischer von Weikersthal, Volker Heinemann, Ursula Vehling-Kaiser, Frank Kullmann
Publikováno v:
European journal of cancer (Oxford, England : 1990). 79
Background RAS and BRAF mutations have been identified as negative prognostic factors in metastatic colorectal cancer. Efficacy of 5-fluorouracil, leucovorin, irinotecan (FOLFIRI) plus bevacizumab in patients with RAS-mutant tumours needs to be furth
Autor:
Charitini Salla, Despoina Georgiadou, Olga Riccioni, Prodromos Kanavidis, Theodora Psaltopoulou, Theodoros N. Sergentanis, Ioannis Ntanasis-Stathopoulos, Diamantis I. Tsilimigras
Publikováno v:
European journal of cancer (Oxford, England : 1990). 79
The diagnosis and treatment of squamous cell carcinoma of the pancreas pose dilemmas in the clinical practice. The present study was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Eligible ar
Autor:
Ralf Gutzmer, Jonathan S. Zager, Carsten Weishaupt, Kelly Markey, Lisa Zimmer, Jochen Utikal, Zeynep Eroglu, Nikhil I. Khushalani, Angela M. Krackhardt, Svetomir N. Markovic, Lucie Heinzerling, Carmen Loquai, Andrea Forschner, Dirk Schadendorf, Lisa A. Kottschade, Susmitha Apuri, Richard W. Joseph, Max Schlaak, Vernon K. Sondak, Simone M. Goldinger
Publikováno v:
European journal of cancer (Oxford, England : 1990). 75
Background The anti-programmed cell death-1 (PD-1) inhibitors pembrolizumab and nivolumab alone or in combination with ipilimumab have shown improved objective response rates and progression-free survival compared to ipilimumab only in advanced melan
Autor:
Laurence Brugières, Carine Bellera, Nadège Corradini, Natacha Omer, Sophie Piperno-Neumann, Perrine Marec-Berard, Marie-Cécile Le Deley, Antoine Italiano, Nathalie Gaspar
Publikováno v:
European journal of cancer (Oxford, England : 1990). 75
Background The most appropriate design of Phase-II trials evaluating new therapies in osteosarcoma remains poorly defined. Objective To study consistency in phase-II clinical trials evaluating new therapies for osteosarcoma recurrences with respect t
Autor:
Anne-Sophie Hamy, Fabien Reyal, Marc Espié, Brigitte Sigal-Zafrani, Philippe Bertheau, Michel Marty, Frédérique Berger, Marie-Christine Mathieu, Etienne Brain, Jean-Yves Pierga, Suzette Delaloge, Jean Marc Guinebretière, O Tembo, chafouny mazouni, Sylvie Giacchetti, Bernard Asselain, Florence Lerebours, Mahasti Saghatchian
Publikováno v:
European journal of cancer (Oxford, England : 1990). 75
Background The REMAGUS-02 multicenter randomised phase II trial showed that the addition to neoadjuvant chemotherapy (NAC) of trastuzumab in patients with localised HER2-positive breast cancer (BC) increased the pathological complete response (pCR) r